Karen Reitsma joins the management team of Rexgenero

03/10/2016

London, UK. Rexgenero Ltd appoints Karen Reitsma as Vice President, Clinical and Regulatory Development. Karen is an expert in the clinical development of cell therapies in Europe and the United States and brings extensive experience in complex cell therapies. Karen has previously held senior roles in clinical development at HAL Allergy, Kiadis, INC Research, Merck Serono and in academic research.

Ixaka Appoints Karen Miller as Chief Scientific Officer

12/07/2022

London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power…

Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001

27/06/2022

REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…

Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area

21/03/2022

London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…

innovative cell therapies